Purpose The rates of cardiovascular implantable electronic device (CIED) implantations and cardiac ablation procedures are increasing worldwide. To date, the management of CIED lead thrombi in the peri-ablation period remains undefined and key clinical management questions remained unanswered. We sought to describe the clinical course and management strategies of patients with a CIED lead thrombus detected in the peri-ablative setting. Methods We performed a retrospective analysis of all patients who underwent a cardiac ablation procedure at Mayo Clinic Rochester from 2000 to 2014. Patients were included in our study cohort if they had documented CIED lead thrombus noted on peri-ablation imaging studies. Electronic medical records were reviewed to determine the overall management strategy, outcomes, and embolic complications in these patients. Results Our overall cohort included 1833 patients, with 27 (1.4 %) having both cardiac ablation procedures as well as CIED lead thrombus detected on imaging. Of these 27 patients, 21 were male (77 %), and the mean age was 59.2 years. The mean duration of follow-up was 16.5 months (range 3 days-48.3 months). Anticoagulation was an effective therapeutic strategy, with 11/14 (78.6 %) patients experiencing either resolution of the thrombus or reduction in size on re-imaging. For atrial fibrillation ablation, the most common management strategy was a deferment in ablation with initiation/intensification of anticoagulation medication. For ventricular tachycardia ablations, most procedures involved a modified approach with the use of a retrograde aortic approach to access the left ventricle. No patient had any documented embolic complications. Conclusions The incidence of lead thrombi in patients undergoing an ablation was small in our study cohort (1.4 %). Anticoagulation and deferral of ablation represented successful management strategies for atrial fibrillation ablation. For patients undergoing ventricular tachycardia ablation, a modified approach using retrograde aortic access to the ventricle was successful. In patients who are not on warfarin anticoagulation at the time of thrombus detection, we recommend initiation of this medication, with a goal INR of 2-3. For patients on warfarin at the time of thrombus detection, we recommend an intensification of anticoagulation with a goal INR of 3.0.
Introduction
Over the last decade, rates of cardiovascular implantable electronic device (CIED) implantations are increasing worldwide [1] [2] [3] [4] [5] [6] [7] . With an aging population, increasing life expectancy, advancement in technology, and broadening of clinical indications for insertion of cardiac devices [8, 9] , this number is predicted to continue to rise. Paralleling the rise of device implantation is the number of patients undergoing cardiac ablation procedures [10] [11] [12] [13] . As a consequence of expanded CIED indications and increasing use of catheter ablation to treat arrhythmias, cardiologists will face more patients undergoing cardiac ablations with CIEDs.
There is minimal data examining the impact of CIED on ablation procedures, with some highlighted concerns relating to an increased risk for developing venous complications, especially thrombosis [14] [15] [16] and subsequent embolization [17] . It has been recently reported that mobile lead thrombosis is a frequent discovery, occurring in 30 % of individuals undergoing ablations [18] . During an ablation, access to either the left ventricle or left atrium is attempted by transseptal puncture. The identification of lead thrombi raises practical concerns due to the subsequent risk for stroke from embolization of lead thrombi through the iatrogenic patent foreman ovale (PFO) [19, 20] . Therefore, when a lead thrombosis is present, there is much hesitancy in proceeding with transseptal puncture and ablation is often aborted.
Despite our ability to detect intracardiac device lead thrombus; the management of these in an ablative environment to date remains elusive. Many key questions remain unanswered: What happens to those that are noticed to have a lead thrombus? How are these individuals managed? Do they experience any embolic phenomena? What is their natural history? With a lack of clear guidance in the management of lead thrombus in an ablative environment, the aim of our study was to systematically review our experience with patients who had a mobile thrombus detected on a CIED lead by peri-ablation imaging to define their clinical course and management.
Methods

Study population
We retrospectively reviewed the electronic medical record at Mayo Clinic Rochester from 1 January 2000 to 31 December 2014 to identify those patients that had a detected lead thrombus noticed on peri-ablation echocardiogram (either intracardiac (ICE), transesophageal (TEE), or transthoracic echocardiogram (TTE)). The chart was electronically searched for the keywords "lead thrombus," "lead mass," "lead clot," and "mobile echodensity." Patients were included if they fulfilled the following criteria: (1) undergoing or planned cardiac ablation, (2) detection of lead thrombus on peri-ablation imagining. To determine the incidence of the lead thrombus, we reviewed all ablations and determined CIED status at the time of ablation through the use of a combination of diagnosis (CIED in situ) and billing codes (which address periprocedural CIED device adjustment and interrogation). Patient characteristic data was collected through examination of the patient electronic medical record. Device data was collected from the nearest device check before the ablation procedure. If the patient happened to undergo placement of either an atrial or ventricular lead at a different time, the age of the lead with the thrombus was calculated. Baseline echocardiographic data was collected from the closest echocardiogram to the ablation date.
Results
Baseline demographics
Twenty-seven patients with a CIED were discovered to have a lead thrombosis on peri-ablative imaging (12 peri-ablation TEE/TTE, 15 I.E. with a mean follow-up of 16.5 months (range 3 days-48.3 months). Baseline demographic data is shown in Table 1 . Patients were predominately male (21/27, 78 %) with a mean age of 59.2 ± 14.1 years. Indication for the ablation was predominately atrial fibrillation and ventricular tachycardia (both 48.1 %). A majority of patients had atrial fibrillation at baseline (19/27, 70.3 %). Cardiomyopathy was common (66.7 %) with an average ejection fraction of 45.8 ± 17.0 (ischemic cardiomyopathy the most common type). Table 2 summarizes the device characteristics. ICD was the most common CIED (16/27, 59.3 %), with average age of device 38 months and average age of leads 106.1 months. The mean right ventricular systolic pressure (RVSP) was 32.5 ± 11.4 mmHg. Four patients had a documented patent foramen ovale determined by both bubble and Doppler evaluation.
Incidence of lead thrombus
Based upon the review of our charts and review of periablation imaging performed, we identified that 1833 (18 % of total ablations during the time period) ablations occurred on individuals with a CIED during the defined time period. The incidence of lead thrombus in patients with a CIED who underwent an ablation was determined to be 27/1833 (1.4 %).
Detection and characteristics of thrombus
ICE was the superior imaging modality for detection of thrombus. Thrombus was not reported on routine TTE in 9 patients (but noticed on TEE and ICE), while both TTE and TEE did not visualize thrombus in 5 patients despite visualization with ICE. The lead thrombus was detected on the atrial lead in 10/ 27 cases and on the ventricular lead in 17/27 cases, with an average size of 16.1 × 8.4 mm. Figure 1 highlights the different management approaches and outcomes across our cohort. In those undergoing AF ablations, the most common approach was to defer the ablation procedure, with very few proceeding. In those patients undergoing a VT ablation, thrombi inhibited the use of transseptal access and many required retrograde aortic access to access the left ventricle. Preceding the ablation, 15 patients (55 %) were receiving anticoagulation, 13 were on warfarin, and 2 were on rivaroxaban. All patients received coagulation in our cohort post identification of the thrombus. Table 3 shows the impact of anticoagulation upon thrombus resolution. Eleven of 14 (78.6 %) patients experienced either resolution of the thrombus or reduction in size with the use of warfarin, either from initiation or intensification (defined as goal INR > 3.0) of anticoagulation. In the 8 patients who experienced complete resolution of the thrombus, 6 were initiated on warfarin, and 2 underwent intensification. In those already on warfarin (n = 5), intensification to achieve a higher INR > 3.0 was a successful strategy with 4/5 having either a reduction or resolution of the thrombus.
Management of thrombus
Outcomes
Five patients who had resolved thrombus underwent repeat procedures with no complications at an average length to repeat procedure of 3.4 ± 1.9 months. No patient had documented embolic compilations related to lead thrombosis over the follow-up period.
Discussion
CIED mobile thrombus is reported to occur in 30 % of patients [18] undergoing an ablation procedure, however the management of these thrombi remains undefined. We are the first to report on long-term outcomes and management of CIED lead thrombus in patients undergoing a cardiac ablation. In this retrospective series, the incidence of lead thrombus is low (1.4 %), and we highlight that the most common management approach in AF ablations was to defer the ablation with initiation or intensification of anticoagulation. In those undergoing VT ablation, modification of the procedure was performed with retrograde aortic access. These were largely successful strategies. Over our follow-up period, clinical sequelae, in particular embolization from these thrombi, were minimal.
We determined the incidence of lead thrombus to be 1.4 % at our institution. Our data is similar to Rabher et al. [21] who reported lead thrombus in 1.4 % of their population who underwent a TTE. Our incidence is smaller when compared to Supple et al. [18] , who reported thrombus at 30 %. We hypothesize that our incidence is smaller because most of these imaging studies were not looking specifically for lead thrombus. Some thrombus is small and therefore may be difficult to detect unless one is specifically looking for it and there are added human factors such as operator experience, In our cohort, the most common management strategy of CIED lead thrombus was to defer the ablation procedure with anticoagulation. This represents a successful approach with most patients (n = 9, 64.3 %) eventually having a repeat ablation or planning a repeat ablation in the near future. The concern with proceeding to ablation in those with CIED lead thrombus is transseptal access, which is frequently performed to access the left side of the heart during cardiac procedures.
By performing transseptal access, an iatrogenic ASD is created and there is a risk that thrombi for the lead may dislodge and subsequently enter the left heart causing paradoxical embolization. Nevertheless, it has to be recognized that 2 patients proceeded with transseptal access despite the inherent risk. The actual risk of proceeding with transseptal puncture is not clearly defined and may also be a safe approach as these patients did not experience any adverse outcome. In both of these patients, the decision to proceed was based upon clinical symptoms, with one patient having highly symptomatic atrial fibrillation and the other with incessant VT and concern for further deterioration in ventricular function and hemodynamic compromise. Although the procedure was not associated with any adverse outcome, given the potential devastating impact of an embolism should clinical circumstances allow, we would still recommend deferring the procedure with anticoagulation.
The impact of anticoagulation (warfarin) on thrombus in general is well acknowledged among the medical community. However, its role in the management of lead thrombus has not been reported in those undergoing a cardiac ablation. Our study confirms that anticoagulation is an effective management strategy to enable clot dissolution (Table 3) . Initiation of warfarin was successful in resolving and reducing thrombus in 8/10 patients (80 %) while intensification of warfarin (n = 5) to an INR of 3.0 was associated with resolution in 2 patients and reduction in 1. In those patients on warfarin who did not undergo intensification, one experienced reduction and another experienced no change in thrombus size. Based upon this data, we propose a two-pronged approach to anticoagulation (Fig. 2) . In those who are not on anticoagulation, initiation of warfarin with an INR of 2-3 will result in dissolution of the thrombus in a large majority of cases. In those already on warfarin, we recommend an intensification of warfarin to an INR 3.0, to enable thrombus resolution. The impact of warfarin on lead thrombi tells us mechanistically that these are likely to be truly thrombotic in nature Fig. 1 Impact of thrombus on cardiac ablation procedure and are not fibrotic. We hypothesize that those already on warfarin get benefit from intensification as they likely have a lack of time with a therapeutic INR [22, 23] (a significant issue, well recognized in patients taking warfarin). Therefore, initiation of a higher goal enables more time in the therapeutic window. Our data supports the study by Rahbar et al. [21] , where they showed that the initiation of intensified anticoagulation therapy resulted in reduction or shrinkage of thrombus in 9 of their patients whom they had follow-up data on. The one major limitation of their study is that they only used TTE as the imaging modality. The concern regarding the sensitivity of TTE to identify thrombus is emphasized in our results, wherein a significant number of patients (n = 5) did not have thrombus identified on regular TTE or TEE imaging but later diagnosed with ICE. Therefore, in their study, it is unclear if those that were recorded as dissolved truly dissolved or simply shrunk in size and were not visible to repeat TTE. Supple et al. [18] reported similar data; it was noted that thrombus was not reported on any routine TTE in 26 patients who had detected mobile thrombus. This underlies the importance of ICE in the detection of lead thrombus. ICE is a relatively new addition to the electrophysiologists' armamentarium, and there is growing data showing it to have increased diagnostic accuracy in the diagnosis of CIED thrombus [24] .
In our cohort, we did observe thrombus across a variety of devices and leads ( Table 2 ). The most common device type in whom we detected thrombus was an ICD. The average age of the device was 38 months, with a mean lead age of 106 months. The average number of leads in our patients was 2, with most having both atria and ventricular leads. Ventricular leads were the most common site of thrombus.
Given the small number of patients in our study, it is difficult to deduce any association between device/lead characteristics and risk of thrombus; future study of this could potentially help identify those patients at greatest risk.
Embolic phenomena from these thrombi are a major concern. However, no recorded embolic events occurred in our cohort. There is data to suggest that lead thrombus is associated with a significant increase in pulmonary artery pressure. Persistent thromboembolism from endocardial leads has been proposed as a potential mechanistic cause for this increase [18] . We did not find an increased RVSP among our patients with lead thrombus. Further evidence from a large study of 5646 CIED patients highlighted that the PE rate was low and suggests that it is possible that embolism of lead thrombus is uncommon or emboli are too small to cause consequential pulmonary infarction [25] . We would agree with these findings based upon our data.
While we are reporting on our experience with lead thrombus and show that anticoagulation represents a successful management approach, it is important to note a few limitations of this study. Its retrospective nature largely inhibits the ability to detect embolic phenomena from these thrombi as some may have had embolic events outside the Mayo Health System network. Further, as we were only reporting on our experiences, we have no comparison group in which thrombus was detected and anticoagulation was not given. In addition, the operators of the peri-ablative imaging may not have been looking exclusively for lead thrombus and therefore lead thrombus may not have been specifically recorded, coded, or put in the ablation procedure report/note potentially leading to underreporting, which could have influence on the low incidence that we observed. Lastly, different imaging modalities Fig. 2 Flowchart highlighting the management of anticoagulation in peri-ablative lead thrombus detection on the follow-up of the lead thrombus limited our ability to have larger numbers to determine the impact of anticoagulation. Further prospective studies are needed to truly determine the incidence of lead thrombus.
Conclusion
We have demonstrated in this retrospective study that the incidence of lead thrombi in patients undergoing an ablation is small at 1.4 %. Initiation of anticoagulation and deferral of ablation represents a successful management strategy in those receiving an AF ablation. In those requiring left ventricular access for VT ablation, retrograde aortic modification is a successful approach.
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